First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $340M — +20.0% growth in a single year.
What Moves the Stock
1Medicare reimbursement policy changes for advanced wound care products, particularly LCD (Local Coverage Determination) updates affecting Apligraf and PuraPly
2Quarterly revenue growth rates and sales force productivity metrics, especially new account additions in the hospital and wound care center channels
3Gross margin trends reflecting product mix shifts between higher-margin Apligraf and lower-margin dermal products
4Operating expense leverage and path to sustained profitability, given the company's current breakeven status
5Clinical trial results and new product launches in the surgical biologics pipeline
6Advanced Wound Care products (estimated 70-75% of revenue) - Apligraf, Dermagraft, PuraPly for chronic wounds including diabetic foot ulcers and venous leg ulcers
7Surgical & Sports Medicine products (estimated 20-25%) - ReNu, NuShield for soft tissue repair and orthopedic applications
8Contract manufacturing and other services (estimated 5-10%)
growth - The company attracts growth-oriented investors focused on the regenerative medicine theme and 11.3% revenue growth…
Rising interest rates have minimal direct impact on operations given low debt levels (0.11 Debt/Equity)…
Watch on earnings: Medicare reimbursement rates and coverage policies for advanced wound care (LCD updates from MACs), Diabetes prevalence rates and aging demographics (65+ population growth) driving chronic wound incidence, Healthcare utilization trends including wound care center visits and hospital admissions for diabetic complications.
One Sentence Summary:
Organogenesis: the story is balanced — medicare reimbursement policy changes for advanced wound care products, particularly lcd (local coverage determination) updates affecting.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.